Document is current
Any future updates will be listed below
-
Authors
Corsten, Cato E. A. https://orcid.org/0000-0001-6531-6979
Geraedts, Veerle S. A.
Marques, Ana M.
Melief, Marie-José
Koelewijn - van Vliet, Barry
van Rooij, Jeroen
Ciaccio, Marcello
Agnello, Luisa
Kuhle, Jens
Tintu, Andrei N.
Wokke, Beatrijs
Smolders, Joost https://orcid.org/0000-0001-9766-8661
-
Funding
Funding for this research was provided by:
Nationaal MS Fonds (Educational grant P2021-001)
Nationaal MS Fonds (Project OZ2021-016)
Stichting MOVES ‘Klimmen tegen MS’ (Inspiratiebeurs)
Siemens Healthineers
- License Information
-
More Information
Article History
Received: 9 December 2025
Revised: 26 January 2026
Accepted: 27 January 2026
First Online: 9 February 2026
Declarations
:
: C. Corsten, V. Geraedts, A. Marques, M.J. Melief, B. Koelewijn – van Vliet, J. van Rooij, M. Ciaccio, L. Agnello, A. Tintu, and B. Wokke report no competing interests. J. Kuhle received speaker fees, research support, travel support, and/or served on advisory boards by Swiss MS Society, Swiss National Research Foundation (320030_212534/1), University of Basel, Progressive MS Alliance, Alnylam, Argenx, Bayer, Biogen, Bristol Myers Squibb, Celgene, Immunic, Merck, Neurogenesis, Novartis, Octave Bioscience, Quanterix, Roche, Sanofi, Stata DX. J. Smolders reports grants for scientific research from Biogen, Roche, and Siemens Healthineers and received a speaker and/or consultancy fee from Biogen, Merck, Novartis, Roche, and Sanofi.
: The Medical Ethical Committee of the Erasmus MC Rotterdam approved the study protocol (MEC-2021-0946).
: Written informed consent was obtained from all participants.
